Last news
Cebu Pacific Rolls Out an Early Christmas Surprise with 12.12 Seat Sale

Cebu Pacific Rolls Out an Early Christmas Surprise with 12.12 Seat Sale

Fares as Low as HKD 1 MANILA, Philippines, Dec. 8, 2025 /PRNewswire/ -- Cebu Pacific (PSE: CEB), the Philippines' leading carrier, spreads holiday cheer early as it unwraps its 12.12 Super Seat Fest, giving travelers the chance to treat themselves...

Inspur Showcases Modular Construction Capability in Brisbane as Demand for Faster, Scalable Delivery Grows

Inspur Showcases Modular Construction Capability in Brisbane as Demand for Faster, Scalable Delivery Grows

Industry Leaders Examine Compliance Pathways, AI-Enabled Delivery Models, and Practical Strategies for Deploying Modular Projects Across Australia BRISBANE, Australia, Dec. 8, 2025 /PRNewswire/ -- On December 5, 2025, Shandong Inspur Intelligent...

Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

NANJING, China, Dec. 8, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company",...

IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH

IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH

SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 8, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell...

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...

Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

BALLARAT, Australia, Dec. 8, 2025 /PRNewswire/ -- Federation University Australia is the type of university where students feel seen, supported and set up for success. Their campuses stretch across Victoria - from the welcoming regional communities...

Daesang Group's "Vietnam Scholarship Quiz Show" Advances Youth Talent Development Through Respect

Daesang Group's "Vietnam Scholarship Quiz Show" Advances Youth Talent Development Through Respect

Record participation as over 100,000 students nationwide compete in Vietnam's premier academic quiz show Hanoi student Đ inh B ả o Khanh earns top honor, receives a 200 million VND scholarship SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Daesang...

Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- The Dulwich College Ranjit Murugason Sustainability Fund is pleased to announce renewed support from LGT Bank Singapore ("LGT"), reinforcing a three-year collaboration that has helped Dulwich College...

1 ... 847 848 849 850 851 852 853 854 855 ... 4131
menu
menu